Sai Life Sciences is expanding capacity and moving into peptides and formulations as global pharma companies diversify supply chains beyond China. The company expects stronger H2FY27 revenue and earnings, supported by new capacity, late-stage molecules and long-term FTE contracts.
Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.